Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume → Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad) Free ATRA Stock Alerts $0.66 -0.03 (-4.44%) (As of 04:20 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Atara Biotherapeutics Short Interest DataCurrent Short Volume11,230,000 sharesPrevious Short Volume11,030,000 sharesChange Vs. Previous Month+1.81%Dollar Volume Sold Short$7.79 millionShort Interest Ratio / Days to Cover3.7Last Record DateMarch 31, 2024Outstanding Shares119,360,000 sharesPercentage of Shares Shorted9.41%Today's Trading Volume1,626,239 sharesAverage Trading Volume2,770,860 sharesToday's Volume Vs. Average59% Short Selling Atara Biotherapeutics ? Sign up to receive the latest short interest report for Atara Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatATRA Short Interest Over TimeATRA Days to Cover Over TimeATRA Percentage of Float Shorted Over Time Ad Behind the MarketsThe #1 Opportunity of the decade?It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.Click here to learn more >>> Atara Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202411,230,000 shares $7.79 million +1.8%N/A3.7 $0.69 3/15/202411,030,000 shares $6.85 million +8.8%N/A3.2 $0.62 2/29/202410,140,000 shares $7.89 million -6.7%N/A2.8 $0.78 2/15/202410,870,000 shares $8.39 million +44.4%N/A2.9 $0.77 1/31/20247,530,000 shares $4.70 million +2.7%N/A1.3 $0.62 1/15/20247,330,000 shares $5.27 million -20.2%N/A1.4 $0.72 Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20239,190,000 shares $4.71 million -9.3%N/A1.9 $0.51 12/15/202310,130,000 shares $6.08 million -8.8%N/A2.2 $0.60 11/30/202311,110,000 shares $7.33 million +36.2%N/A2.8 $0.66 11/15/20238,160,000 shares $3.10 million -34.7%N/A2.2 $0.38 10/31/202312,490,000 shares $16.11 million +1.8%N/A6.1 $1.29 10/15/202312,270,000 shares $18.90 million +6.3%N/A10.5 $1.54 9/30/202311,540,000 shares $17.08 million -1.1%N/A9.5 $1.48 9/15/202311,670,000 shares $17.86 million +1.2%N/A9.7 $1.53 8/31/202311,530,000 shares $16.83 million -5.4%N/A7.5 $1.46 8/15/202312,190,000 shares $22.43 million -5.9%N/A6.9 $1.84 7/31/202312,950,000 shares $28.62 million +2.6%N/A6.9 $2.21 7/15/202312,620,000 shares $23.09 million +7.9%N/A6.7 $1.83 6/30/202311,700,000 shares $18.84 million -11.4%N/A6 $1.61 6/15/202313,200,000 shares $28.25 million +4.6%N/A7 $2.14 5/31/202312,620,000 shares $19.31 million -11.0%N/A7.6 $1.53 5/15/202314,180,000 shares $31.20 million -20.3%N/A10 $2.20 4/30/202317,790,000 shares $48.21 million -7.4%N/A13.8 $2.71 4/15/202319,210,000 shares $51.67 million -3.8%N/A15.9 $2.69 3/31/202319,960,000 shares $57.88 million +19.5%N/A17.1 $2.90 3/15/202316,700,000 shares $51.44 million +18.7%N/A13.1 $3.08 2/28/202314,070,000 shares $56.98 million +0.4%N/A11.3 $4.05 2/15/202314,010,000 shares $63.47 million -1.3%N/A11.4 $4.53 1/31/202314,190,000 shares $71.94 million +4.1%N/A10.3 $5.07 1/15/202313,630,000 shares $53.02 million +4.8%N/A9.5 $3.89 12/30/202213,010,000 shares $42.67 million +5.0%N/A9.1 $3.28 12/15/202212,390,000 shares $42.87 million +1.2%N/A8.4 $3.46 11/30/202212,240,000 shares $55.45 million +1.6%N/A8.4 $4.53 11/15/202212,050,000 shares $60.37 million +1.1%N/A7.7 $5.01 10/31/202211,920,000 shares $55.55 million +0.2%N/A6.9 $4.66 10/15/202211,900,000 shares $44.39 million -3.4%N/A5.7 $3.73 9/30/202212,320,000 shares $46.57 million -0.2%N/A4.6 $3.78 9/15/202212,350,000 shares $58.05 million +10.2%N/A4.7 $4.70 8/31/202211,210,000 shares $44.95 million -0.6%N/A4.4 $4.01 8/15/202211,280,000 shares $60.24 million +7.0%N/A4.7 $5.34Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> ATRA Short Interest - Frequently Asked Questions What is Atara Biotherapeutics' current short interest? Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 11,230,000 shares of ATRA short. Learn More on Atara Biotherapeutics' current short interest. What is a good short interest ratio for Atara Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 4.0. Learn More on Atara Biotherapeutics's short interest ratio. Which institutional investors are shorting Atara Biotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Atara Biotherapeutics: Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Atara Biotherapeutics' short interest increasing or decreasing? Atara Biotherapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 11,230,000 shares, an increase of 1.8% from the previous total of 11,030,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Atara Biotherapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Atara Biotherapeutics: Athira Pharma, Inc. (2.86%), AlloVir, Inc. (5.48%), Passage Bio, Inc. (3.57%), Gritstone bio, Inc. (9.40%), Cognition Therapeutics, Inc. (0.53%), Precision BioSciences, Inc. (8.03%), Curis, Inc. (0.85%), Semper Paratus Acquisition Co. (0.25%), Elutia Inc. (0.14%), Instil Bio, Inc. (0.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Atara Biotherapeutics stock? Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atara Biotherapeutics? A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further. How often is Atara Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: ATHA Short Interest Data ALVR Short Interest Data PASG Short Interest Data GRTS Short Interest Data CGTX Short Interest Data DTIL Short Interest Data CRIS Short Interest Data LGST Short Interest Data ELUT Short Interest Data TIL Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATRA) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe #1 Crypto for 2024InvestorPlaceYour Money is Not SafeAmerican Alternative